Clinical Trial Update: Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating lapatinib in patients with recurrent or metastatic prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Lapatinib (Lapatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Prostate Cancer, Stage IV Prostate Cancer | Phase 2 | Status: COMPLETED